Cytomegalovirus Pneumonitis Is a Risk for Bronchiolitis Obliterans Syndrome in Lung Transplantation.
Evidence level: retrospective single-centre cohort (231 recipients); abstract-only
A single-centre cohort of 231 lung transplant recipients reporting that treated cytomegalovirus pneumonitis was associated with a higher hazard of BOS and death.
As of . Primary source: Publisher record via DOI.
Summary
According to the abstract, 231 consecutive recipients transplanted between 2000 and 2004, all receiving short-course ganciclovir prophylaxis, were followed with transbronchial biopsies at defined intervals and prospective CMV immunostaining on every biopsy (1,887 biopsies). Forty-nine recipients (21 percent) developed CMV pneumonitis a median of 106 days after transplant. Treated CMV pneumonitis within the first 6 months was associated with an increased risk of BOS (hazard ratio 2.19, 95 percent confidence interval 1.36 to 3.51) and of death (hazard ratio 1.89, 1.11 to 3.23), including in time-dependent and multivariable models. The authors state that more effective preventive strategies are needed. The design shows association in one programme and one era of prophylaxis.
Details
- doi
- 10.1164/rccm.200911-1786OC
- pmid
- 20167845
- authors
- Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM
- journal
- American Journal of Respiratory and Critical Care Medicine
- year
- 2010
- volume
- 181
- issue
- 12
- pages
- 1391-1396
- publishedOnline
- 2010-06-15
Sources and links
- Publisher record via DOI (primary)
- PubMed 20167845
Related
Links from this record
- discusses: Bronchiolitis obliterans syndrome (BOS)
Linked from (derived)
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- full author affiliations (only the PubMed affiliation text was checked for named centres)
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.